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Human cytochrome P450 1A2 is an important drug metabolizing enzyme, similar in 
sequence to P450 1A1, but with distinct substrate specificity.  Previously, we have shown 
that residue 382 affected 1A1 and 1A2 specificities with alkoxyresorufins.  To determine 
whether this residue is also important for the metabolism of other substrates, we have 
investigated phenacetin oxidation by single (T124S, T223N, V227G, N312L and L382V) 
and multiple (L382V/T223N, L382V/N312L, L382V/T223N/N312L and 
L382V/T124S/N312L) mutants of P450 1A2.  The enzymes were expressed in 
Escherichia coli and purified.  All P450 1A2 mutants that contained the Leu-382→Val 
substitution displayed much higher activities than the wild type enzyme, with kcat values 
3-fold higher, in contrast to other mutants, for which kcat decreased.  Likewise, a 
significant increase in specificity, expressed as the kcat/Km ratio, was observed for the 
mutants containing the L382V substitution.  The efficiency of coupling of reducing 
equivalents to acetaminophen formation was decreased for all single mutants except 
L382V, for which the coupling increased.  This was also observed with multiple 1A2 
mutants containing the L382V substitution.  Low activities of the four other single 
mutants were likely due to dramatically increased uncoupling to water.  In contrast, the 
increase in activity of the L382V-containing mutants resulted from decreased water 
formation.  This is consistent with molecular dynamics results, which showed decreased 
phenacetin mobility leading to increased product formation.  The results of these studies 
confirm the importance of residue 382 in P450 1A2-catalyzed oxidations and 






Cytochromes P450 (P450s) are heme-containing monooxygenase enzymes, which are 
involved in the metabolism of numerous exogenous and endogenous compounds.  P450s 
are ubiquitous in living organisms, with at least 50 families and 82 subfamilies found in 
different species.  Human P450 1A subfamily has two major isoforms: P450 1A1 and 
1A2.  P450 1A2, one of the major P450s in the human liver, was first characterized as a 
phenacetin O-deethylase (Distlerath et al., 1985).  Currently, it is estimated that this 
enzyme metabolizes approximately 11% of all drugs in humans (Shimada et al., 1994).  
Despite the fact that P450 1A2 participates in the deactivation and detoxification of 
xenobiotics, the main interest in this enzyme is because of the metabolic activation of a 
large number of chemical carcinogens (Guengerich and Shimada, 1991; Levis et al., 
1994).    
 
In humans, P450 1A2 shares 72% amino acid sequence identity with P450 1A1, but 
the substrate specificities and inhibitor susceptibilities of these enzymes are different.  
For example, substrates such as phenacetin and 7-methoxyresorufin are primarily 
metabolized by P450 1A2 with high catalytic efficiency, while P450 1A1 displays weak 
capability to oxidize those substrates.  On the other hand, 7-ethoxyresorufin is 
preferentially oxidized by P450 1A1 (Nerurkar et al., 1993; Burke et al., 1994).  The 
structural basis for such functional differences between highly related enzymes can be 
investigated using a variety of techniques, including molecular modeling and 




structure of P450 1A2 was solved by X-ray crystallography (Sansen et al., 2007), and 
thus it provides a practical model for structure-function studies.   
Our previous studies on structure-function relationships of P450 1A1 indicated that 
Val-382 played an important role in binding of alkoxyresorufin substrates (Liu et al., 
2003).  The sequence alignment between P450 1A1 and 1A2 indicated that five active 
site residues that are different between these enzymes (Ser-122, Asn-221, Gly-225, Leu3-
12 and Val-382 in 1A1 and the corresponding residues in 1A2: Thr-124, Thr-223, Val-
227, Asn-312 and Leu-382) might be involved in determining substrate specificity (Liu et 
al., 2004).   This was confirmed by the finding that five reciprocal mutations in P450 1A1 
and 1A2 altered enzymatic activity with alkoxyresorufins as substrates.  Moreover, 
mutations at position 382 in both P450 1A1 and 1A2 shifted substrate specificity from 
one enzyme to another (Liu et al., 2004).  Further computational and experimental studies 
with multiple P450 1A2 mutants confirmed the importance of this residue for 
alkoxyresorufin oxidation (Tu et al., 2008).  Therefore, it would be of interest to examine 
the effect of these mutations on oxidation of other types of substrates. 
 
In the current study, we chose phenacetin as a substrate.  This compound has been 
used as the most common marker for P450 1A2 activity in the in vitro studies of 45% of 
new drugs by investigators in the pharmaceutical industry (Yuan et al., 2002).  The 
objective of the present study was to investigate whether any reciprocal mutations in 
P450 1A2 may alter phenacetin oxidation and to examine the potential mechanism(s) that 
might be involved.  A total of five single mutants, and four multiple mutants containing 




modeling and experimental methods.  These included enzyme kinetics and stoichiometry 
studies, as well as molecular dynamics simulations of phenacetin in the active site of 
P450 1A2 mutants to facilitate the interpretation of experimental results.  This study 
should provide an increased understanding of the biochemical aspects of substrate 




Materials and Methods 
 
Materials.  Phenacetin, acetaminophen, 2-hydroxy acetanilide, sodium dithionite, 
NADPH, ampicillin, isopropyl-β-D-thiogalactopyranoside (IPTG), δ-aminolevulinic acid 
(ALA), 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate (CHAPS), 
dilauroyl-L-3-phosphatidyl choline (DLPC) and phenylmethanesulfonyl fluoride (PMSF) 
were from Sigma-Aldrich Chemical (St. Louis, MO).  Nickel-nitrilotriacetic acid-agarose 
and a gel extraction kit were purchased from Qiagen (Valencia, CA).  Potassium 
phosphate, EDTA, acetic acid and HPLC grade methanol were purchased from Fisher 
Scientific (Pittsburgh, PA).  All other chemicals used were of analytical grade and were 
obtained from standard commercial sources.   
 
Protein Expression and Purification.  The clones of P450 1A1 WT, 1A2 WT and 
single mutants, T124S, T223N, V227G, N312L and L382V, all of them containing a His-
tag for easy purification, were constructed earlier (Liu et al., 2003; 2004).  P450 1A2 His-
tag multiple mutants, L382V/T223N, L382V/N312L, L382V/T223N/N312L and 
L382V/T124S/N312L, were also constructed previously (Tu et al., 2008).  The P450 
enzymes were expressed in E. coli DH5α cells and purified essentially as previously 
described (Liu et al., 2004; Tu et al., 2008).  During the purification, the addition of 5 
mM caffeine in the purification buffers helped to stabilize P450 1A2 proteins.  The 
substrate caffeine was removed completely from the enzyme preparation during the 
ultrafiltration stage, as verified by HPLC.  Rat cytochrome P450 reductase was expressed 




purity of the enzymes was assessed by SDS-PAGE.  Western blots were performed using 
anti-human P450 1A1/1A2 (Oxford Biomedical, Oxford, MI) and P450 proteins were 
visualized as described (Kedzie et al., 1991).  P450 content was determined by reduced 
CO/reduced difference spectra (Omura and Sato, 1964) and protein was measured by the 
method of using Folin phenol reagent (Lowry et al., 1951). 
 
P450 Activity Assay.  Phenacetin O-dealkylase activities of P450 1A2 WT and 
mutants were determined by HPLC measurements as described previously (von Moltke et 
al., 1996), with some modifications.  The reaction mixtures contained 0.5 μM P450 1A2, 
1 μM P450 reductase, 45 μM DLPC in 100 mM potassium phosphate buffer (pH 7.5). 
The enzymes and DLPC were pre-incubated for 2 minutes at 37°C before the dilution.  
For kinetic assays, phenacetin was added at concentrations ranging from 0 to 1000 μM, 
and the mixture was incubated for another 3 minutes at 37°C.  The reaction was initiated 
by adding NADPH to a final concentration of 1 mM in a total volume of 1 mL, and 
conducted for 30 minutes.  The reaction was terminated by the addition of 5 µL of 60% 
HClO4 and the reaction mixture was put on ice for 10 minutes.  10 µL of 100 μM 2-
hydroxy acetanilide was then added as an internal standard for HPLC determination.  The 
reaction mixture was centrifuged at 103g for 5 minutes, and 100 µL of the supernatant 
was removed and used directly for HPLC analysis.  The product acetaminophen was 
eluted from a C18 column (Alltech associates Inc, Deerfield, IL) with a mobile phase of 
methanol/0.1% acetic acid (30:70, v/v; flow rate 1.5 mL.min-1), and monitored at 254 nm.  




(Vmax and kcat) were calculated using nonlinear regression with GraphPad Prism software 
(San Diego, CA).  
 
Binding Constant Determination.  Spectral binding constants for phenacetin bound 
in the active site of P450 1A1 WT and 1A2 enzymes were obtained using difference 
visible spectroscopy (Modi et al., 1995).  Solutions (800 µL) contained 0.5 µM P450 1A2 
WT or the mutants in 100 mM phosphate buffer, containing 20% glycerol and 0.1 mM 
EDTA, pH 7.4. 2 µL of different concentrations of solutions of phenacetin in menthol 
were added to the sample cuvette, and the same volume of menthol was added to the 
reference and UV spectra were then recorded.  The data was analyzed by nonlinear 
regression analysis using Microsoft Excel software. 
 
NADPH Oxidation.  The rate of NADPH oxidation was determined 
spectrophotometrically at 340 nm in a cuvette thermostated at 37°C.  The reaction 
mixture was similar to that used for phenacetin assay, and contained 0.5 μM P450 
enzyme, 1 μM P450 reductase, 45 μM DLPC and 1 mM phenacetin in a 100 mM 
potassium phosphate buffer, pH 7.5, in a volume of 980 µL.  The reaction was initiated 
by the addition of 20 µL of 50 mM NADPH.  The NADPH oxidation rates were recorded 
for about 3 minutes at 340 nm from the beginning of the reaction.  The molar extinction 
coefficient of 6.22 mM-1 cm-1 for NADPH at 340 nm was used to obtain oxidation rates 
in nmol min-1 (nmol P450)-1.  Three 50 µL aliquots of the reaction mixture were removed 
after 1, 2, and 3 minutes, and quenched with 50 µL of 10% CF3COOH.  The triplicate 





Hydrogen Peroxide Production.  The reaction mixtures from NADPH oxidation 
assay were used to measure the production of hydrogen peroxide (H2O2) using the 
xylenol orange iron (III) assay (Jiang et al., 1990; Fang et al., 1997), with slight 
modifications.  The coloring agent was prepared by mixing 100 volumes of 125 µM 
xylenol orange in 100 mM sorbitol and 1 volume of 25 mM of fresh ferrous (Fe2+) 
ammonium sulphate in 2.5 M H2SO4.  The calibration curve was prepared using the 
quenched reaction mixture which was supplemented with hydrogen peroxide at 
concentrations ranging from 0 to 10 µM.  The H2O2 standard solutions were prepared 
fresh on the day of the assay by dilution of a 30% H2O2 stock solution.  The reaction 
mixture was incubated at room temperature for an hour. Absorbance was recorded using 
a Beckman spectrophotometer set at 560 nm to obtain the concentration of H2O2 
produced in nmol min-1 (nmol P450)-1.  
 
Oxygen Consumption.  The reaction was conducted using a Mitocell (Strathkelvin 
Instruments Limited, Glasgow, U.K.) which was connected to a water bath thermostated 
at 37°C.  The reaction mixture was prepared in a similar way to that for the NADPH 
oxidation assay.  980 µL of the sample was placed in the chamber of the Mitocell and 
once a steady baseline was established, the reaction was initiated by the addition of 20 µL 
NADPH.  The oxygen consumption was recorded over 5 min as µmol L-1 hour-1, which 





Molecular Modeling Methods: General. Molecular modeling simulations were 
conducted using a Silicon Graphics Octane workstation with Insight II software 
(Accelrys, San Diego, CA).  The crystal structure of P450 1A2 (pdb code: 2hi4) was 
obtained courtesy of Dr. Eric F. Johnson, The Scripps Research Institute, La Jolla, CA 
(Sansen et al., 2007).  The heme cofactor was removed and replaced with the oxoheme 
cofactor.  Substrate phenacetin was constructed with Insight II/Builder module, and 
optimized.  The models of P450 1A2 single and multiple mutants were constructed from 
the crystal structure of 1A2 WT by the replacement of selected amino acid(s) and further 
refinement of the structures according to the previously established procedure (Liu et al., 
2003; 2004, Tu et al., 2008).  Molecular dynamics (MD) simulations and energy 
minimization were carried out using the Insight II/Discover module with the consistent 
valence force field (CVFF) supplemented with parameters for heme and ferryl oxygen, as 
described earlier (Paulsen and Ornstein, 1991; 1992).  The non-bond cutoff was 16 Å, 
and all other parameters were set at their default values.  Structural refinement of P450 
1A2 WT and mutants involved 1000 steps of minimization using steepest descent 
gradient followed by 10 ps MD and then another 1000 steps of steepest descent 
minimization.    The optimized structures were used for the subsequent docking studies. 
 
Docking of Phenacetin into the Active Site of P450 1A2 WT and Mutants.  
Initially, phenacetin was manually placed into the active site of P450 1A2 WT and the 
mutants on the distal side of the oxoheme.  Docking of phenacetin was performed with 
Insight II/Affinity module using default parameters, as described previously (Liu et al., 




phenacetin position comprised the flexible region of the receptor (P450 1A2 WT and 
mutants) during all docking runs.  The Affinity docking method utilizes both the Monte 
Carlo (MC) search technique and simulated annealing (SA) approach followed by the 
minimization protocol to generate low-energy substrate binding orientations.  A distance-
dependent dielectric constant was applied to simulate charge screening by water 
molecules.  Ten lowest-energy phenacetin binding orientations obtained from Affinity 
docking were selected for further analysis.   
 
Molecular Dynamics (MD) Simulations of Enzyme-Substrate Complexes.   MD 
simulations were performed to investigate phenacetin mobility in the active site and the 
effect of mutations on substrate orientation.  The starting configuration for MD 
simulations chosen from Affinity docking represented the productive binding orientation 
of phenacetin leading to its O-dealkylation, and had the lowest potential energy rank.  
The MD simulations of each phenacetin-enzyme complex were performed at 310 K in 
vacuo essentially as described earlier (Liu et al., 2004; Tu et al., 2008).  The substrate, 
heme and protein residues within 10 Å from the initial substrate position were flexible 
without any restraints, while the remainder of the protein was fixed.  A distance-
dependent dielectric constant was used to simulate aqueous environment, and the non-
bond cutoff distance was 16 Å.  After 5 ps MD equilibration phase, the MD simulations 
were continued for 100 ps, and 400 frames obtained every 250 fs were extracted to record 
the snapshots of each enzyme-substrate complex.     
 Additionally, to evaluate the effect of explicit solvent on phenacetin dynamics in the 




complexes using a similar protocol.  The enzymes chosen were P450 1A2 WT and the 
L382V mutant.  The enzyme-substrate complexes were solvated using crystallographic 
water molecules from P450 1A2 crystal structure and optimized prior to MD with 1000 
steps of steepest descent minimization using a non-bond cutoff of 16 Å and dielectric 
constant of 1.  Similar to previous MD simulations, only protein residues, heme, substrate 
and solvent within a 10 Å radius of the initial substrate position were permitted to move, 
while the remainder of the protein and other water molecules were fixed.  This insures 
that none of the moving solvent molecules escape from the vicinity of the active site.  In 
contrast to previous MD simulations, the flexible region also included 21 water 
molecules surrounding phenacetin.  For the aqueous simulations, the dielectric constant 
was set to 1.  All other parameters were the same as for the previous enzyme-substrate 
simulations without explicit solvent present.  
All MD trajectories were examined using Insight II/Analysis module.  To score the 
likelihood of hydroxylation, each sampled frame of a given enzyme-substrate complex 
was evaluated using the following geometric criterion: r ≤ 3.5 Å and θ ≥ 120˚, where r 
represents the distance between the ferryl oxygen and the hydrogen of the substrate to be 
abstracted; θ represents the angle between ferryl oxygen, the hydrogen atom to be 
abstracted, and the carbon at the oxidation site, as described previously (Ericksen and 
Szklarz, 2005; Tu et al., 2008).  Trajectory data from 100 ps MD simulations were 
extracted and graphed using Microsoft Excel.  The MD frames where the geometric 
criterion, r ≤ 3.5 Å and θ ≥ 120˚, was satisfied, were counted as hits.  The number of hits 







 Kinetics of Phenacetin O-Deethylation by P450 1A2 WT and Mutants.  P450 1A2 
enzymes were expressed in E. coli and purified.  The overall yield of the procedure was 
about 20-40%, similar to that reported previously (Liu et al., 2004; Tu et al., 2008). The 
purity of P450 1A2 WT and mutants verified by SDS-PAGE and Western blots indicated 
that they were at least 95% pure.  The spectrum of the FeII-CO complex exhibited a 
characteristic peak at 450 nm, with little or no P420 formation.  The holoenzyme content 
of the enzymes was usually in the range of 40-60%, as previously observed in our 
laboratory.   
Kinetic parameters, kcat, Km and substrate specificity (kcat/Km), were determined for 
purified P450 1A2 WT and mutants using a range of substrate phenacetin concentrations.  
Phenacetin undergoes O-deethylation to form acetaminophen as the main product of the 
reaction.  Kinetic parameters for P450 1A2 WT and mutants are shown in Table 1.  
Compared to P450 1A2 WT, the mutations affected both kcat and Km.  Interestingly, the 
P450 1A2 L382V mutant and multiple mutants containing the Leu-382→Val mutation 
displayed 2-fold or 3-fold higher kcat than the wild type enzyme.  Four other single 
mutants, namely T124S, T223N, V227G, and N312L, exhibited much lower kcat than the 
WT.   
As shown in Table 1, the Km values for 1A2 WT and mutants varied greatly. 
Generally, the Km values for all the mutants were more than 50% lower than for the wild 
type (~60 μM).  The lowest values of Km were observed for several mutants containing 




L382V/T124S/N312L (~10 μM), which suggests that the Leu-382→Val mutation 
significantly increased the binding affinity of the enzyme for phenacetin.  The substrate 
specificities of the L382V mutant and multiple mutants containing the Leu-382→Val 
mutation, expressed as kcat/Km, were at least 5-fold higher than that of the WT (Table 1). 
In particular, the relative substrate specificities of L382V and L382V/T223N mutants 
were over 20-fold higher, which is extremely high.  
Incidentally, phenacetin is less efficiently metabolized by P450 1A1 WT, (kcat 0.5 
min-1 and KM 66 μM), with kcat close to one third of the value observed with P450 1A2 
WT (see Table 1) and the kcat/Km  ratio lower than 0.01.    
Phenacetin binding constants were also determined for P450 1A2 WT and some 
mutants.  P450 1A2 WT and the N312L mutant showed similar phenacetin binding, with 
binding constants of 17.1 μM and 10.2 μM, respectively.  In contrast, the L382V and the 
L282V/N312L mutants displayed much lower values for binding constants, namely 0.7 
μM and 3.5 μM, indicating tighter substrate binding.  Interestingly, P450 1A1 WT 
exhibited much weaker binding, with a binding constant of 57 μM.      
 
Stoichiometry of Phenacetin O-Deethylation.  To assess whether the Leu-382→Val 
mutation affected P450 1A2 coupling efficiency of reducing equivalents to 
acetaminophen formation, stoichiometry experiments were conducted.  The rates of 
NADPH oxidation, hydrogen consumption, product formation, hydrogen peroxide and 
excess water production for phenacetin oxidation by P450 1A2 WT and mutants are 
shown in Table 2.  The excess water formation was calculated from the difference 




formation (Excess H2O = NADPH – H2O2 – product).  The amount of water was also 
obtained from the difference between the rate of oxygen consumption and rates of 
hydrogen peroxide plus product formation (H2O = 2(O2 – H2O2 – product)), as reported 
by others (Fang et al., 1997), giving the values which were very similar (within 5%) to 
those derived from the previous equation (data not shown).  The coincubation of 
phenacetin with P450 1A2 L382V and three multiple mutants, L382V/T223N, 
L382V/N312L and L382V/T223N/N312L, resulted in consumption of both NADPH and 
oxygen by the mutants at rates ~2-fold greater than those with the wild type enzyme.  
Likewise, the formation of product acetaminophen as well as byproducts such as 
hydrogen peroxide and water, were 2-3-times higher in the case of these mutants.  The 
exception was the L382V/T124S/N312L mutant, which seemed to utilize NADPH at a 
rate similar to the WT enzyme, but displayed increased consumption of oxygen, along 
with increased product and hydrogen peroxide formation.  On the other hand, four single 
mutants, T124S, T223N, V227G and N312L, are similar or less efficient than the WT 
with respect to NADPH oxidation, oxygen consumption, hydrogen peroxide, and water 
production, but exhibit a substantial decrease in product formation.     
Table 3 presents the effects of mutations on the coupling efficiency of P450 1A2, 
both overall and at specific P450 uncoupling branching points.  The ratios of product 
formation to NADPH oxidation, accounting for the overall efficiency of P450 1A2 
coupling of reducing equivalents to product, were higher for L382V and multiple mutants 
containing the L382V substitution than for the WT.  In contrast, other single mutants, 
T124S, T223N, V227G and N312L, exhibited significantly decreased coupling 




displayed similar ratios of H2O2 production to O2 consumption, which suggests that the 
mutations had no effect on uncoupling at the first and second branching points of the 
P450 cycle.  On the other hand, significant differences between the enzymes were 
observed with respect to the H2O: product ratios used to measure uncoupling at the third 
branching point.  Thus, for the L382V mutant and multiple mutants containing the Leu-
382→Val substitution, these ratios were generally lower than that for the WT, while for 
the other single mutants, these ratios were 3-fold higher.   Therefore, low activities of the 
four single mutants were likely due to dramatically increased uncoupling to water, 
whereas the increase in activity in the L382V-containing mutants resulted from decreased 
water formation.       
 
Molecular Modeling Analyses.  Using the crystal structure of P450 1A2, molecular 
modeling studies have been conducted to understand the effects of single and multiple 
mutations on enzyme-substrate interactions and substrate mobility, and to explain the 
alterations of catalytic efficiency.  Figure 1 depicts binding orientations of phenacetin 
within the active sites of P450 1A2 WT and the L382V mutant.  In general, the binding 
orientation of phenacetin in both enzymes was very similar.  However, the replacement 
of Leu-382 by a smaller Val increased the volume of the active site and allowed the 
hydrogens at the oxidation site of phenacetin to approach closer to the ferryl oxygen of 
the heme, which facilities hydrogen abstraction.  The average distance between the 
hydrogens at the oxidation site of phenacetin and the ferryl oxygen of the L382V mutant 
was 3.1 Å, compared to 3.7 Å for the WT enzyme.  Similar results were also obtained for 




oxidation site of phenacetin were much farther away from the ferryl oxygen in the active 
sites of T124S, T223N, V227G, and N312L mutants (data not shown).  These findings 
correlate well with the results of kinetic and stoichiometric studies described above, and 
suggest that the substitution of Leu-382 with Val not only increases catalytic efficiency 
(kcat) of P450 1A2 but also decreases Km and enzyme uncoupling.  
In order to examine the tendency of phenacetin to remain in the productive binding 
orientation in the active site of the enzyme, 100 ps of molecular dynamics (MD) 
simulations were performed, as described in Materials and Methods.  After the 5 ps MD 
equilibration phase, the energy of the system remained constant throughout the 
simulations.  The mobility of the substrate varied with the mutant: we observed fairly low 
mobility for the WT enzyme, L382V, T124S and L382V/T223N/N312L mutants, with 
RMSD from the initial substrate orientation of 1-2 Å, moderate mobility for V227L and 
N312L mutants with RMSD of 2-4 Å, and a high phenacetin mobility in the case of 
T223N and L382V/T223N mutants (RMSD > 4 Å).       
    The productive binding orientations of phenacetin were determined using 
geometric parameters, distance r and angle θ, as described in Materials and Methods.  
These parameters were then plotted based on 400 recorded snapshots for each enzyme-
substrate complex.  The representative plots, those for P450 1A2 WT, N312L, L382V, 
and L382V/T223N mutants, showing the ensembles of substrate orientations, are 
presented in Fig. 2.  The region where the geometric criterion (r ≤ 3.5 Å and θ ≥ 120˚) is 
satisfied is gray, and the points (or frames) located within represent all snapshots of each 
enzyme-substrate complex where phenacetin was bound in the productive binding 




displayed varied.  Overall, phenacetin showed higher occupancy within a productive 
binding region (counted as hits) in the L382V and L382V/T223N mutants than in the WT.  
Similar results were also seen in the case of other multiple mutants containing L382V 
(data not shown), while few hits if any were observed for the remaining four single 
mutants, as shown for the N312L mutant (Fig. 2b).   A quantitative analysis of the hits for 
each enzyme-substrate complex revealed that the number of hits for L382V, 
L382V/T223N, and L382V/T223N/N312L mutants were 2-fold, 4-fold and 5-fold higher, 
respectively, than that for the WT (Table 4).  In contrast, zero or few hits were obtained 
for T124S, T223N, V227G, and N312L mutants during 100 ps dynamics.  It is possible 
that some hits might be recorded during a longer simulation time.  Overall, the results of 
MD simulations are, like those from docking experiments, consistent with the kinetic and 
stoichimetric analyses of P450 1A2 WT and mutants.  
A possible drawback of the simulations described above might have been the 
utilization of the distance-dependent dielectric constant instead of explicit solvent.  
Therefore, we have also conducted MD simulations of phenacetin docked in the active 
site of P450 1A2 WT and the L382V mutant with the solvent molecules present and the 
dielectric constant of 1.  In the presence of water, 70 hits were recorded for the WT 
enzyme and 144 hits for the L382V mutant.  Thus, in both cases, the percentage of hits 
increased less than 10% and to a very similar extent (9.4% for the WT and 7.5% for the 
mutant) compared to the results from MD simulations without water (see Table 4).  This 
indicates that, although some changes may be observed with solvent present, simulations 
with distance-dependent dielectric provide a reasonable approach to explain the observed 






Our previous studies indicated that residue 382 plays an important role in controlling 
the specificity of alkoxyresorufin O-dealkylation by P450 1A1 and 1A2 (Liu et al., 2003; 
2004; Tu et al., 2008).  Since phenacetin is another important probe substrate for P450 
1A2, the studies to address the effects of reciprocal mutations, particularly Leu-382→Val, 
on phenacetin oxidation, may broaden our understanding of the role of this residue in 
substrate specificity.  In the present study, a total of 9 single and multiple mutants were 
investigated using a battery of complementary approaches, such as kinetic assays, 
stoichiometry measurements and molecular modeling methods.  The results demonstrated 
that the substitution of Leu-382 with Val resulted in a significant increase in catalytic 
activity and substrate specificity of P450 1A2.  Interestingly, all multiple mutants that 
contained this substitution displayed very similar kinetics, stoichiometry, and dynamic 
mobility as the single L382V mutant.  Thus, the presence of this single residue was 
critical for dramatically improving the efficiency of phenacetin oxidation by P450 1A2. 
To date, many residues of P450 1A2 have been identified that may play a role in 
enzyme-ligand interactions by site-directed mutagenesis and/or molecular modeling 
studies (Yun et al., 2000; Liu et al., 2004; Zhou et al., 2009).  In the case of  single 
mutants, most of the mutations, including T124S, T223N, V227G, and N312L in the 
present study, resulted in decreased catalytic activity and substrate specificity compared 
to the wild-type enzyme (Parikh et al., 1999; Liu et al., 2004).  A number of P450 1A2 
mutants obtained from random mutagenesis showed increased catalytic activities and 




highly active as the L382V mutant reported in this study (Table 1).  It is worth 
mentioning that the kinetic parameters for phenacetin O-dealkylation by P450 1A2 WT 
determined in the present investigation were very similar to those reported by Parikh et al. 
(1999).  Although the Leu-382→Val mutation dramatically increased oxidation of 
phenacetin, it led to a significant decrease in 7-methoxyresorufin O-dealkylation (Liu et 
al., 2004).  Thus, the functional effect of residue substitution appears to be dependent on 
the substrate (Zhou et al., 2009).   
Moreover, the binding constants determined for P450 1A2 WT and mutants showed 
that the substitution of Leu-382 with Val leads to tighter phenacetin binding in the active 
site of the L382V-containing mutants, consistent with enzyme kinetics results.  This may 
increase phenacetin residence time resulting in higher activity. 
In order to better explain the effects of mutations on catalytic activity and substrate 
specificity of P450 1A2, stoichiometry studies were performed.  The coupling 
efficiencies of different mutants, expressed in terms of product:NADPH, H2O2:O2, and 
H2O:product ratios,  were compared to those of WT.  A similar approach has been used 
by Fang et al. (1997) and Kobayashi et al. (1998) to evaluate coupling efficiencies of 
P450 2B1 mutants.  Frequently, the mutation decreases the coupling efficiency of the 
P450, as observed with P450 2B1 (Fang et al., 1997; Kobayashi et al., 1998) and 
P450cam (French et al., 2002), but the effect depends upon the substrate.  Previously 
studied P450 1A2 mutants showed only a small increase in coupling efficiency with 
phenacetin as a substrate (Yun et al., 2000), in contrast to our results with the L382V-
containing mutants.  In the present studies, the L382V mutant and multiple mutants 




reducing equivalents to acetaminophen formation than the WT (Table 3).  In general, the 
increased ratios of product:NADPH for the L382V mutant and multiple mutants and the 
decreased ratios for T124S, T223N, V227G, and N312L mutants were in agreement with 
the kinetic data regarding phenacetin turnover rates.  Although no significant changes of 
uncoupling to H2O2 at the first and the second branching points were observed in all the 
mutants, those which contained the Leu-382→Val substitution showed less uncoupling to 
water (decreased H2O:product ratio, Table 3).  Thus, it seems reasonable to suggest that 
the substitution of Leu-382 with Val in P450 1A2 yields the mutants that utilize NADPH 
and O2 more efficiently to oxidize phenacetin to products and display less uncoupling to 
water, so that the overall coupling efficiency of the enzyme increases, which is consistent 
with enzyme kinetics results (Table 1).  
Molecular modeling studies provide another possible explanation of the effects of 
mutations on phenacetin specificity, as indicated by changes in kinetic parameters.  For 
these simulations, we used the X-ray structure of P450 1A2, and the structures of the 
mutants were derived from the crystal.  As reported by Sansen et al. (2007), this P450 
1A2 structure has a closed compact active site, without clear solvent or substrate access 
channels, with a relatively small volume of the cavity, estimated at 375 Å3.  The active 
site of 1A2 is about 44 % larger than that of P450 2A6 (260 Å3) and significantly smaller 
than that of P450 3A4 (1385 Å3) (Sansen et al., 2007).  Consequently, only planar 
compounds, such as α-naphthoflavone (ANF), and typical P450 1A2 substrates such as 
phenacetin, 7-ethoxyresorfin, caffeine, tacrine or theophylline can be fitted well with the 
narrow and flat active site cavity of enzyme.  Leu-382 of P450 1A2 is a critical residue 




volume of the active site near heme.  This allows phenacetin to move closer to heme, so 
that one of the hydrogens at the oxidation site is within a hydrogen-bonding distance 
from the ferryl oxygen (Fig. 1), which promotes hydrogen abstraction.  This is consistent 
with the MD results (Table 4, Fig. 2).  Consequently, the movement of phenacetin closer 
to the ferryl oxygen in the L382V mutants helps to explain not only the substantial 
increase in kcat and a decrease in Km for the production of acetaminophen (Table 1), but 
also more efficient coupling of the P450 reaction cycle with less water formation (Table 
3).  
Molecular dynamics simulations similar to those described in this work have been 
successfully used in our previous studies for fairly rapid predictions or interpretation of 
experimental results (Ericksen and Szklarz, 2005; Tu et al., 2008).  The present studies 
suggest that the use of the distance-dependent dielectric constant can be a reasonable 
substitute for the presence of explicit water molecules.  We have observed only a small 
increase in the percentage of hits (less than 10%) from MD simulations with water.      
These conclusions may be further verified by more extensive MD simulations of the 
complete protein-substrate complexes on nanosecond time-scales.  Recently, longer 2 ns 
MD simulations have been successfully used to predict the effect of mutations on the 
catalytic efficiency of P450 2B6 (Nguyen et al., 2008).  
In summary, our results demonstrate that the substitution of Leu-382 with Val in 
P450 1A2 can alter the binding orientation of phenacetin within the active site of the 
enzyme, so that the site of metabolism moves closer to the heme iron.  This provides a 
good mechanistic explanation for the increased catalytic efficiency as well as coupling 




substitution.  The current studies also demonstrate that a combination of several 
experimental approaches with molecular modeling methods can improve our  
understanding of P450 catalysis.  These different methodologies complement each other 
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Legends for Figures 
 
 
FIGURE 1.  Binding orientation of phenacetin within the active site of P450 1A2 WT (A) 
and the L382V mutant (B).  The protein backbone is depicted as a blue ribbon, the side 
chain of residue 382 is green, with van der Waals surface displayed, heme is red, and 
phenacetin is yellow, with hydrogens at the oxidation site shown in red.  The distance 
between the hydrogen to be abstracted and the ferryl oxygen (marked with a black line) is 
3.6 Å in the WT and 2.9 Å in the L382V mutant. 
 
FIGURE 2.  Ensembles of substrate orientations obtained from 100 ps MD simulations of 
phenacetin-enzyme complexes described by geometric parameters, distance r and angle θ.  
H1 in –OCH2– group of phenacetin is blue and H2 is red.  Grey regions, where the 
criterion (r ≤ 3.5 Å and θ ≥ 120˚) is satisfied, represent productive binding orientations of 
phenacetin within the active site.  P450 1A2 enzymes were: WT (A), N312L mutant (B), 





















-1 min-1)b [(kcat/Km)mutant/(kcat/Km)WT] 
WT 1.28±0.08 59.70±1.82 0.02±0.01 1.00 
T124S 0.29±0.03 28.90±1.10 0.01±0.01 0.47 
T223N 0.30±0.01 26.99±0.01 0.01±0.01 0.52 
V227G 0.38±0.02 32.36±2.93 0.01±0.01 0.55 
N312L 0.31±0.01 25.26±0.01 0.01±0.01 0.57 
L382V 3.03±0.06 5.75±0.57 0.53±0.04 24.77 
L382V/T223N 3.91±0.10 7.77±0.80 0.51±0.06 23.65 
L382V/N312L 3.05±0.15 16.14±2.05 0.19±0.02 8.87 
L382V/T223N/N312L 3.67±0.10 32.42±11.31 0.12±0.04 5.61 
L382V/T124S/N312L 2.81±0.03 10.13±2.40 0.28±0.07 13.34 
 
a Data are means of triplicate determinations.  







Rates (nmol min-1 (nmol P450-1)) determined for phenacetin metabolism by P450 1A2 wild-type and mutantsa 
 
aData are means of triplicate determinations.  
bExcess water (H2O) was calculated from the equation: H2O= NADPH – H2O2 – product 
P450 1A2 NADPH oxidized O2 consumed Product formed H2O2 produced Excess  H2O
b 
WT 43±4 22.7±0.9 1.28±0.08 14±2 15±2 
T124S 27±2 14.8±0.4 0.29±0.03 10±0 9±1 
T223N 41±3 17.3±0.7 0.30±0.00 10±1 14±2 
V227G 40±3 16.9±0.5 0.38±0.02 9±1 15±2 
N312L 32±2 18.3±0.3 0.31±0.00 13±2 10±1 
L382V 84±6 47.0±1.3 3.03±0.06 29±3 30±4 
L382V/T223N 98±7 57.9±2.5 3.91±0.10 38±3 32±5 
L382V/N312L 70±4 41.0±2.0 3.05±0.15 29±3 18±3 
L382V/T223N/N312L 72±5 41.7±1.1 2.18±0.03 28±3 23±3 





Effect of mutations on coupling efficiency of P450 1A2 at different branching points of P450 cyclea 
P450 1A2 Product/NADPHb H2O2/O2
c                 H2O/Product
d 
    WT                0.030 0.62 11.72 
    T124S 0.011 0.68 31.03 
    T223N 0.007 0.58 46.67 
    V227G 0.010 0.53 39.47 
    N312L   0.010 0.71 32.26 
    L382V 0.036 0.62 9.9 
    L382V/T223N    0.040 0.66 8.18 
    L382V/N312L    0.044 0.71 5.9 
    L382V/T223N/N312L    0.030 0.67 10.55 
    L382V/T124S/N312L    0.087 0.76 2.45 
 
aRatios were calculated from parameters in Table 2. 
bEfficiency of coupling reducing equivalents to product. 










Geometric analysis of molecular dynamics results for P450 1A2 WT and mutants  
Hits represent the MD frames where phenacetin was in the productive binding orientation, as 


























P450 1A2 Number of Hits 
WT 64 
T124S 0 
T223N 0 
V227G 4 
N312L 0 
L382V 134 
L382V/T223N 252 
L382V/T223N/N312L 308 


